Phage Pharmaceuticals, Inc. is a private, San Diego-based biopharmaceutical company. Our core business is our clinical pipeline consisting of therapeutic products for tympanic membrane perforation, wound healing, and cardiovascular indications, as well as a vaccine adjuvant. The Company maintains IND’s for the clinical development of our lead compound – recombinant fibroblast growth factor-1 (FGF-1).Phage’s management team has extensive experience in the pharmaceutical and biotechnology industry encompassing commercial management, drug discovery and development, facility planning, drug manufacture, finance, and business development.
We are also developing a biosimilar pipeline, including human growth hormone (hGH), interferon alpha, and granulocyte colony-stimulating factor (GCSF). Phage maintains an IND for the development of the human growth hormone (hGH).
In addition, we are developing a cosmetic line with anti-aging serum as a lead product, and bacteriophage based antimicrobial therapy for treatment of microbial diseases in humans and animals.
The Company maintains a cGMP (current Good Manufacturing Practice) licensed production facility for manufacturing of recombinant proteins under contract to an established U.S. based contract manufacturing organization, and also has capability to produce bacteriophages for clinical and research applications.